1. Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities

2. Activity Goals

3. Extended Follow-up CLL8 (GCLLSG)

4. CLL5 Protocol: Overall Survival

5. PFS in Patients > 70 y: Across Treatment Regimens

6. Fludarabine (F) vs Chlorambucil (Ch) by Age Group < or > 65 y

7. PFS: Ch vs Bendamustine (B) in Untreated CLL

8. Ch + Rituximab (R) in Symptomatic, Previously Untreated CLL

9. Ch + R in Symptomatic, Previously Untreated CLL

10. Targeting of BCR Signaling With Ibrutinib

11. Phase 2 (PCYC-1102-CA) in CLL/SLL

12. Phase 2: Best Response by Risk Features

13. Phase 2: PFS

14. Phase 2: PFS by Prognostic Factors

15. Ibrutinib and Rituximab (IR) in High-Risk CLL

16. Transient Lymphocytosis on IR in High-Risk CLL

17. Lymph Node Responses Assessed by CT (31 Evaluable Patients)

18. Idelalisib + Rituximab in Frontline CLL

19. Nodal Response: Idelalisib + Rituximab

20. Response: Idelalisib + Rituximab

21. PFS: Idelalisib + Rituximab

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)